Showing results (271-280 of 285) with videos related to
Sort By:
Pageof 29
Journal of Hepatology|January 1, 2017
Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosisThomas Karlas, David Petroff, Magali Sasso, et al.Lancet (London, England)|February 16, 2019
Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort studyFabrice Carrat, Hélène Fontaine, Céline Dorival, et al.Journal of Hepatology|May 15, 2013
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890Christophe Hézode, Hélène Fontaine, Céline Dorival, et al.Journal of Viral Hepatitis|November 1, 2018
Non-virological factors are drivers of hepatocellular carcinoma in virosuppressed hepatitis B cirrhosis: Results of ANRS CO12 CirVir cohortSegolene Brichler, Pierre Nahon, Fabien Zoulim, et al.Hepatology (Baltimore, Md.)|June 28, 2016
Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir)Nathalie Ganne-Carrié, Richard Layese, Valérie Bourcier, et al.Gastroenterology|April 8, 2014
Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosisChristophe Hézode, Helene Fontaine, Celine Dorival, et al.Hepatology (Baltimore, Md.)|February 14, 2015
Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort)Jean-Claude Trinchet, Valérie Bourcier, Cendrine Chaffaut, et al.Gastroenterology|July 22, 2018
Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance ProgramsPierre Nahon, Richard Layese, Valérie Bourcier, et al.Gastroenterology|February 16, 2019
Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral TherapyDominique Thabut, Christophe Bureau, Richard Layese, et al.Gut|October 30, 2015
Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort)Pierre Nahon, Mathilde Lescat, Richard Layese, et al.Pageof 29